Real-World Study of Chidamide Combined With PD-(L)1 Inhibitors and Anti-Angiogenic Therapy for Advanced MSS-Type Colorectal Cancer
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Study ID
- NCT06858956
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Chidamide, Tucidinostat; PD-1/PD-L1 inhibitor or double antibodies; Bevacizumab or tyrosine kinase inhibitors — DRUGChidamide, Tucidinostat; PD-1/PD-L1 inhibitor or double antibodies; Bevacizumab or tyrosine kinase inhibitors
Study Details
This is an observational , multicenter, real-world study aimed at evaluating the efficacy and safety of the combination of immune checkpoint inhibitors, chidamide and antiangiogenic agents in Microsatellite Stable advanced colorectal cancer patients.
Key Dates
- First listed
- Mar 5, 2025
- Start date
- Mar 1, 2025
- Status verified
- Feb 2025
- Primary completion
- May 31, 2025
- Completion
- May 31, 2026
Study Design
- Enrollment
- 200 participants (estimated)
Primary Outcome Measure
TTF [ Time Frame: 24 months ]
Central Contacts
- Aiping Zhou, PHD010-87788800
Related Studies
- Evaluation for NCI Surgery Branch Clinical Research ProtocolsRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer PatientsRecruiting · Vanderbilt University Medical Center · Nashville, Tennessee
- ColoCare Study - Colorectal Cancer CohortRecruiting · University of Utah · Los Angeles, California
- Feasibility of the LUM Imaging System for Detection of Gastrointestinal CancersPHASE1/PHASE2 · Recruiting · Lumicell, Inc. · Boston, Massachusetts